Citoxlab appoints Christophe Berthoux as CEO, Europe
This appointment will further drive current and future development of Citoxlab’s European sites, which are already experiencing strong growth
Evreux, France, August 30, 2018 – Citoxlab, a leading CRO for non-clinical research, today announces the hiring of Christophe Berthoux as CEO, Europe.
Christophe Berthoux, a doctor in veterinary medicine, has an MBA from Purdue University (US). He has spent all his 28 year career in the CRO industry. From 1990 to 2004 he was managing director and corporate VP of the Research Models Division at Charles River Laboratories (CRL) Europe. He then moved to the US to lead the clinical division of CRL (2005-2006) before being promoted as executive corporate VP, chief commercial officer for CRL Group (2007-2010). More recently, Berthoux was CEO of Synexus, the worldwide leader in clinical SMO, headquartered in the UK (2010-2017).
Dr. Jean-François Le Bigot, president and CEO of Citoxlab group said: “Following the recent acquisition of Solvo, Citoxlab now has six research centers in Europe (France, Hungary and Denmark). Our growth remains robust in both Europe and North America; more than 20% annually. In this context, it became clear that we needed to reinforce our management structure. I am very happy that Christophe is joining the Citoxlab team as CEO, Europe. I have known Christophe for many years, he has the solid international experience needed for this important position. He is a recognized and respected leader with a successful track-record in the CRO industry. This is a strategic appointment for the future of our company.”
Dr. Christophe Berthoux said: “I am very excited to join Citoxlab, which is the non-clinical CRO with the best growth track record. When I met Jean-François at the beginning of my career, he was the head of CIT, a one site CRO with 120 staff. Today, Citoxlab has become a leading international non-clinical CRO, the 4th largest worldwide, with nine research centers in five countries and more than 1,400 staff; this is very impressive. At this time there are a lot of changes in pharma and biotech R&D. As a scientifically driven CRO, I am convinced that Citoxlab has a lot of opportunities for future growth, organically as well as through carefully selected acquisitions. I am happy to bring my experience to ensure the continued growth of Citoxlab.”
About Citoxlab Group
With nine facilities located in France (Evreux and Saint-Nazaire), Canada (Laval and Boisbriand), the US (Kansas City), Denmark (Copenhagen) and Hungary (Veszprém, Budapest, Szeged), Citoxlab Group offers a comprehensive range of preclinical services to meet the needs of pharmaceutical, biotechnology, medical device, chemical and agrochemical companies worldwide. Citoxlab carries out studies in general and reproductive toxicology, carcinogenicity, immunology, pharmacology, pharmacokinetics and bioanalysis/biomarkers. Citoxlab and Atlanbio also offer both preclinical and clinical bioanalysis and biomarker services. AccelLAB provides efficacy and safety studies of medical devices (cardiology, ENT, orthopedics and regenerative medicine). A partnership with Stemina (Madison, USA) allows the Group to offer screening services using human embryonic stem cell models. With the recently acquired Solvo Biotechnology, products and services in the field of transporters and DDI are now available. Today, Citoxlab has 1,400 employees working at nine sites with state-of-the-art facilities, generating revenues of €150M ($175M). The company has a world-class top-level management team in scientific, financial and business activities.